Age: 81.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Therapeutic response unexpected
Clinical narrative: contracted COVID 2 times more since; developed covid Jun2021; developed covid Jun2021; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  An 81-year-old female patient received BNT162b2 (BNT162B2), on 07Jan2021 as dose 1, single (Batch/Lot number: unknown), in arm and on 28Jan2021 as dose 2, single (Batch/Lot number: unknown) at the age of 81 years, in arm, all intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Alzheimer's", start date: 2019 (ongoing), notes: Pertinent details: From vascular dementia; "vascular dementia" (unspecified if ongoing); "cholesterol" (unspecified if ongoing); "UTI infection" (unspecified if ongoing); "appetite" (unspecified if ongoing). Concomitant medication(s) included: ARICEPT oral taken for dementia alzheimer's type, start date: 2019, stop date: 2022; REMERON oral taken for dementia alzheimer's type, start date: 2019 (ongoing); NAMENDA oral taken for dementia alzheimer's type, start date: 2019 (ongoing); FOLIC ACID oral taken for blood cholesterol, start date: 2019 (ongoing); ZETIA oral taken for blood cholesterol, start date: 2019 (ongoing); MEGESTROL oral taken for appetite disorder, start date: 2019, stop date: 2022; TRIMETHOPRIM taken for urinary tract infection, prophylaxis, start date: 2019, stop date: 2023. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset Jun2021, outcome "unknown" and all described as "developed covid Jun2021"; DISEASE RECURRENCE (medically significant), outcome "unknown", described as "contracted COVID 2 times more since". Clinical course: Patient Diagnosed with Alzheimer's in 2019 due to vascular dementia as characterized by brain mass shrinkage the Parkinsonism symptomology is comorbid and was finally diagnosed 2022. There was no adverse reaction but a positive reaction. After each dose and the booster (Name withheld) demonstrated marked cognitive awareness and functional improvement which could not be explained by medication. Although over time this up tick has faded due to ongoing disease activity, some or more than one component of the Pfizer COVID Vaccine from 2021 and 2022 created a positive. Interaction never logically with (Withheld). No Vaccine is ever 100% effective in disease prevention but in COVID buts it did the job of of Security. Patient reported that both (Name withheld) and myself developed COVID Jun2021 after being on an airplane to and from (State Withheld) to see relatives. We have contracted COVID 2 times more since. No vaccine is ever 100 percent effective. But Security of symptoms and durations was much less than it could've been w/o vaccination  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300029824 Same patient/same product, different dose/event;US-PFIZER INC-202300165802 Same patient/same product, different dose/event;US-PFIZER INC-202300165847 Same patient/same product, different dose/event;